Myomo Inc. · AMEX:MYO
Myomo — Investor Presentation (April 2026)
24 slides from Myomo's investor presentation, April 2026
Slide 1: Investor Presentation April 2026
INVESTOR PRESENTATION APRIL 2026 Paul R. Gudonis, Chairman and CEO David Henry, CFO Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1
Slide 2: Legal Disclaimer
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and
Slide 3: Strategic Positioning
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Strategic Positioning First-Mover Advantage in a Created New Product Large and Growing Market Category with MyoPro with Strong Competitive Myoelectric Orthosis Position CMS Reimbursement and Gr
Slide 4: Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease Stroke TBI Major Dx Other Dx SCI ➢ Stroke/CVA ➢ Cerebral Palsy ➢ Traumatic Brain BPI ➢ Multiple Sclerosis Injury PI ➢ ALS ➢ Sp
Slide 5: Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don’t
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don’t Current Treatment Options Rehabilitation: The Medical Need: ➢ Occupational therapy ➢ Static bracing A lightweight, p
Slide 6: Substantial Market Opportunity
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Substantial Market Opportunity Senior Insured Population 40,000 to We believe the TAM for 400,000 to 80,000 patients replenish the the MyoPro approximately 800,000 patients may 46% prevalence d
Slide 7: Recurring Patient Sources: Rehab Hospitals and O&P’s
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Recurring Patient Sources: Rehab Hospitals and O&P’s ONSET ACUTE SUB-ACUTE OUTPATIENT CHRONIC CARE CARE THERAPY HEMIPARESIS Incidence: (Incidence) (Prevalence) 800,000 Onset → 1 week 1 week → 6
Slide 8: Reimbursement and Contracting Status
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Reimbursement and Contracting Status HCPCS Codes L8701, L8702 for MyoPro ➢ Issued January 2019 ➢ As of January 1, 2024, these codes are in the brace benefit category, meaning lump sum reimburse
Slide 9: Market Access – More Payer Contracts and Covered Lives
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Market Access – More Payer Contracts and Covered Lives 180 158 million covered lives 160 140 45 * * Pending completion Covered Lives in millions 120 of multi-state contracts expected by the end
Slide 10: Enabling a Paralyzed Arm to Move Again
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Enabling a Paralyzed Arm to Move Again 10
Slide 11: MyoPro Powered Arm Brace: Only Device to Restore Function
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials MyoPro Powered Arm Brace: Only Device to Restore Function ➢ MyoPro uses advanced sensor technology as a brain-computer interface to detect the user’s intention to move via the body’s electromyo
Slide 12: Growing our Body of Clinical Research
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Growing our Body of Clinical Research Myoelectric Arm Orthosis Assists Functional Activities: A 3-Month Home Use Outcome Report Influence of a Myoelectric Arm Orthosis. A Minimum 6 to 17-Month
Slide 13: Go-to-Market Approach: How a Patient Obtains a MyoPro
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Go-to-Market Approach: How a Patient Obtains a MyoPro Lead Generation Reimbursement MyoPro Custom Delivery & & Evaluation Approval Fabrication Payment 1 Clinical TV, Social Referrals Media New
Slide 14: Cost-Effective TV Advertising for Target Demographic
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Cost-Effective TV Advertising for Target Demographic 14
Slide 15: 2026 Strategy Direction & Four Success Pillars
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials 2026 Strategy Direction & Four Success Pillars 1. Shift to Recurring Revenue Sources: - MyoConnect Referrals from Rehab Hospitals and O&P Channel 2. Increase Market Access with Additional Payer
Slide 16: Developing a Nationwide Network of Recurring Patient Sources
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials With Reimbursement in Place, We Are Developing a Nationwide Network of Recurring Patient Sources O&P Clinics (COE’s) Payers • Medicare-Accredited Partners • In-Network with Payers • Already Ser
Slide 17: Recurring Patient Sources: Referrals and O&P Channel
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Recurring Patient Sources: Referrals and O&P Channel 60.00% 50%+ 50.00% 42% 40.00% 30.00% 26% 20.00% 10.00% 0.00% 4Q 24 4Q 25 4Q 26 Direct Billing Referrals International U.S. O&P VA Total 17
Slide 18: Key Metrics: Pipeline and Authorizations
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Key Metrics: Pipeline and Authorizations Pipeline Orders: Key to Revenue Growth 1800 250 1600 1528 241 1389 240 1400 233 229 1200 230 Total 225 1000 Medicare 220 800 213 210 207 600 400 200 250
Slide 19: P&L and Key Balance Sheet Metrics
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials P&L and Key Balance Sheet Metrics P&L Key Balance Sheet Metrics Actual Actual Actual Actual Actual Actual ($000's) Q4'25 Q4'24 2025 2024 ($000's) Q4'25 Q3'25 Revenue $ 11,353 $ 12,068 $ 40,928
Slide 20: Key Milestones Driving Revenue Growth
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Key Milestones Driving Revenue Growth Revenues Recurring $M Invest in Revenue Direct Billing Sources + O&P Channel 43-46 Medicare 40-42 Part B China JV revenues license revenue, 32.6 Record Rec
Slide 21: Operating Priorities
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Operating Priorities ➢ Grow patient pipeline at a lower cost per pipeline add. • New Digital Media Agency 42% • Direct-to-Patient and Health Care Providers 26% ➢ Increase revenue from recurring
Slide 22: Summary and Highlights
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Summary and Highlights Summary and Highlights ➢ Record # of Orders in Q4 ➢ New Marketing Head and Digital Agency -> Lower CAC ➢ Growing % of Revenue from Recurring Patient Sources ➢ Revenue Gro
Slide 23: Leadership Team & Board of Directors
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Leadership Team & Board of Directors Management Team Members Board of Directors Paul R. Gudonis Barry Camrell Thomas Kirk Chairman & CEO Lead Independent Director VP of QA/RA Scaled multiple te
Slide 24: Thank You! For Additional Information
Thank You! For Additional Information: Paul R. Gudonis, CEO David Henry, CFO paul@myomo.com david.henry@myomo.com 617-401-2623 508-344-5235 24